Double-blind comparison of 2.5 and 5.0 mg of prostaglandin E2 gel for preinduction cervical ripening

Carl Vernon Smith, Ann Miller, Glenn T. Livezey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: To compare the effectiveness and safety of 2.5 vs. 5.0 mg of prostaglandin E2 (PGE2) gel for preinduction cervical ripening. STUDY DESIGN: Patients presenting for induction of labor with an unfavorable Bishop score (≤4) were assigned randomly, in a double-blind manner, to receive either 2.5 or 5.0 mg of PGE2 gel intravaginally. A repeat Bishop score was determined in four to six hours, and if the score was still unfavorable, the same dose of gel was administered a second time. All patients returned within 12 hours for induction of labor. RESULTS: A total of 119 patients received PGE2 gel, 55 in the 2.5-mg group and 64 in the 5.0-mg group. Both groups were similar with respect to age, parity, race, indication for induction and preinduction Bishop score. Both doses of PGE2 gel were safe and effective. The need for additional doses of gel, the need for and duration of oxytocin use, and the duration of labor were similar in both groups. More infants whose mothers received the 5.0-mg dose had one-minute Apgar scores < 7 (P = .027). No significant difference in five-minute Apgar scores was noted. Cesarean delivery for failed induction was uncommon, occurring in 3.6% of patients who received 2.5 mg and in 4.7% of patients who received 5.0 mg of PGE2 gel (P = NS). Finally, the incidence of hyperstimulation was 3.6% in the 2.5-mg group and 1.6% in the 5.0-mg group (P = NS). Conclusion: A 5-mg dose of PGE2 gel was neither more effective nor associated with more side effects than the more commonly used 2.5-mg dose.

Original languageEnglish (US)
Pages (from-to)745-748
Number of pages4
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Volume41
Issue number10
StatePublished - Oct 1 1996

Fingerprint

Cervical Ripening
Dinoprostone
Gels
Induced Labor
Apgar Score
Oxytocin
Parity
Mothers
Safety

Keywords

  • labor, induced
  • prostaglandin E2

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Double-blind comparison of 2.5 and 5.0 mg of prostaglandin E2 gel for preinduction cervical ripening. / Smith, Carl Vernon; Miller, Ann; Livezey, Glenn T.

In: Journal of Reproductive Medicine for the Obstetrician and Gynecologist, Vol. 41, No. 10, 01.10.1996, p. 745-748.

Research output: Contribution to journalArticle

@article{f3407fdd1f6642f599f9d702fdaa6288,
title = "Double-blind comparison of 2.5 and 5.0 mg of prostaglandin E2 gel for preinduction cervical ripening",
abstract = "OBJECTIVE: To compare the effectiveness and safety of 2.5 vs. 5.0 mg of prostaglandin E2 (PGE2) gel for preinduction cervical ripening. STUDY DESIGN: Patients presenting for induction of labor with an unfavorable Bishop score (≤4) were assigned randomly, in a double-blind manner, to receive either 2.5 or 5.0 mg of PGE2 gel intravaginally. A repeat Bishop score was determined in four to six hours, and if the score was still unfavorable, the same dose of gel was administered a second time. All patients returned within 12 hours for induction of labor. RESULTS: A total of 119 patients received PGE2 gel, 55 in the 2.5-mg group and 64 in the 5.0-mg group. Both groups were similar with respect to age, parity, race, indication for induction and preinduction Bishop score. Both doses of PGE2 gel were safe and effective. The need for additional doses of gel, the need for and duration of oxytocin use, and the duration of labor were similar in both groups. More infants whose mothers received the 5.0-mg dose had one-minute Apgar scores < 7 (P = .027). No significant difference in five-minute Apgar scores was noted. Cesarean delivery for failed induction was uncommon, occurring in 3.6{\%} of patients who received 2.5 mg and in 4.7{\%} of patients who received 5.0 mg of PGE2 gel (P = NS). Finally, the incidence of hyperstimulation was 3.6{\%} in the 2.5-mg group and 1.6{\%} in the 5.0-mg group (P = NS). Conclusion: A 5-mg dose of PGE2 gel was neither more effective nor associated with more side effects than the more commonly used 2.5-mg dose.",
keywords = "labor, induced, prostaglandin E2",
author = "Smith, {Carl Vernon} and Ann Miller and Livezey, {Glenn T.}",
year = "1996",
month = "10",
day = "1",
language = "English (US)",
volume = "41",
pages = "745--748",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "10",

}

TY - JOUR

T1 - Double-blind comparison of 2.5 and 5.0 mg of prostaglandin E2 gel for preinduction cervical ripening

AU - Smith, Carl Vernon

AU - Miller, Ann

AU - Livezey, Glenn T.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - OBJECTIVE: To compare the effectiveness and safety of 2.5 vs. 5.0 mg of prostaglandin E2 (PGE2) gel for preinduction cervical ripening. STUDY DESIGN: Patients presenting for induction of labor with an unfavorable Bishop score (≤4) were assigned randomly, in a double-blind manner, to receive either 2.5 or 5.0 mg of PGE2 gel intravaginally. A repeat Bishop score was determined in four to six hours, and if the score was still unfavorable, the same dose of gel was administered a second time. All patients returned within 12 hours for induction of labor. RESULTS: A total of 119 patients received PGE2 gel, 55 in the 2.5-mg group and 64 in the 5.0-mg group. Both groups were similar with respect to age, parity, race, indication for induction and preinduction Bishop score. Both doses of PGE2 gel were safe and effective. The need for additional doses of gel, the need for and duration of oxytocin use, and the duration of labor were similar in both groups. More infants whose mothers received the 5.0-mg dose had one-minute Apgar scores < 7 (P = .027). No significant difference in five-minute Apgar scores was noted. Cesarean delivery for failed induction was uncommon, occurring in 3.6% of patients who received 2.5 mg and in 4.7% of patients who received 5.0 mg of PGE2 gel (P = NS). Finally, the incidence of hyperstimulation was 3.6% in the 2.5-mg group and 1.6% in the 5.0-mg group (P = NS). Conclusion: A 5-mg dose of PGE2 gel was neither more effective nor associated with more side effects than the more commonly used 2.5-mg dose.

AB - OBJECTIVE: To compare the effectiveness and safety of 2.5 vs. 5.0 mg of prostaglandin E2 (PGE2) gel for preinduction cervical ripening. STUDY DESIGN: Patients presenting for induction of labor with an unfavorable Bishop score (≤4) were assigned randomly, in a double-blind manner, to receive either 2.5 or 5.0 mg of PGE2 gel intravaginally. A repeat Bishop score was determined in four to six hours, and if the score was still unfavorable, the same dose of gel was administered a second time. All patients returned within 12 hours for induction of labor. RESULTS: A total of 119 patients received PGE2 gel, 55 in the 2.5-mg group and 64 in the 5.0-mg group. Both groups were similar with respect to age, parity, race, indication for induction and preinduction Bishop score. Both doses of PGE2 gel were safe and effective. The need for additional doses of gel, the need for and duration of oxytocin use, and the duration of labor were similar in both groups. More infants whose mothers received the 5.0-mg dose had one-minute Apgar scores < 7 (P = .027). No significant difference in five-minute Apgar scores was noted. Cesarean delivery for failed induction was uncommon, occurring in 3.6% of patients who received 2.5 mg and in 4.7% of patients who received 5.0 mg of PGE2 gel (P = NS). Finally, the incidence of hyperstimulation was 3.6% in the 2.5-mg group and 1.6% in the 5.0-mg group (P = NS). Conclusion: A 5-mg dose of PGE2 gel was neither more effective nor associated with more side effects than the more commonly used 2.5-mg dose.

KW - labor, induced

KW - prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=0029861529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029861529&partnerID=8YFLogxK

M3 - Article

C2 - 8913976

AN - SCOPUS:0029861529

VL - 41

SP - 745

EP - 748

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 10

ER -